News

The partial clinical hold was put on the phase 1/2 VELA study after visual adverse events were observed in some patients with solid tumors after treatment with BLU-222.

In an interview with Targeted Oncology, Zev A. Wainberg, MD, discussed the rationale behind NAPOLI 3 and how findings from the study will influence the metastatic pancreatic ductal adenocarcinoma space moving forward.

In phase 1 of the KOMET-001 trial, ziftomenib showed a 30% complete response rate in patients with NPM1-mutant acute myeloid leukemia treated at a dose of 600 mg. This is now the recommended phase 2 dose for the phase 2 portion of the study.

CINtec PLUS Cytology is the only dual-stain triage test to be offered by BioReference Health LLC for patients with a high-risk human papillomavirus result.

John Diaz, MD, discusses some of the targeted therapies that are showing promise for patients with ovarian cancer.

In an 8 to 5 vote, the FDA's Oncologic Drugs Advisory Committee supported the proposed clinical trial for dostarlimab as treatment of locally advanced, treatment-naïve mismatch-repair deficient or microsatellite-instability-high rectal cancer.

A regular approval has been granted to dostarlimab for the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.

Srdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of momelotinib in managing anemia for patients with myelofibrosis.

In an interview with Targeted Oncology, Tara Seery, MD, discussed the rationale and findings from cohort 3 of the QUILT 88 study in metastatic pancreatic cancer.

Based on findings from the ROSALIA study, the FDA has accepted for review a proposed denosumab biosimilar for patients with osteoporosis and treatment-related bone loss in patients with cancer.

In a study examining racial disparities, differences in curative intent, endocrine and/or chemotherapy, frequency and types of treatment-related adverse events, and more were seen in Non-Hispanic Black women vs Non-Hispanic White women with breast cancer.

In an interview with Targeted Oncology, Samuel Klempner, MD, discussed the significance of the phase 3 SPOTLIGHT study and the future impact of claudin 18.2 as a biomarker to treat cancers of the stomach and esophagus.

Wellmarker Bio’s novel therapeutic antibody WM-A1-3389 will be tested with Merck’s pembrolizumab in a phase 1b study of patients with non–small cell lung cancer.

Dermalyser shows the potential to decrease the workload for dermatologists and replace it with an artificial intelligence tool to identify malignant melanomas among cutaneous lesions.

Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the importance of long-term survivorship care and its correlation with quality-of-life in patients with thyroid cancer.

Giuseppe Curigliano, MD, discussed next steps following the HER2CLIMB study in HER2-positive breast cancer.

Results of a study of dabrefenib, trametinib, and spartalizumab showed efficacy for the combination of a BRAF inhibitor, a MEK inhibitor, and an anti–PD-1 agent in patients with BRAF V600-mutated colorectal cancer.

New research of the BTK degrader NX-2127 shows promising results for breaking down resistance to the therapy in the lymphoma and leukemia settings.

In an interview with Targeted Oncology, Jeremy Abramson, MD, discussed findings of the phase 3 TRANSFORM study which were presented at the 2022 American Society of Hematology Annual Meeting.

Early findings from the phase 2 OATH trial show treatment with ONA-XR plus anastrozole elicits a 4-month progression- free survival rate of 77% and overall response rate of 22% in patients with HR-positive metastatic endometrial cancer.

The UPGRADE-A trial assessing the combination of upifitamab rilsodotin and carboplatin in patients with platinum-sensitive high-grade serous ovarian cancer has initiated the dose-expansion portion of the study.

Findings from the DEBBRAH trial showed that the use of trastuzumab deruxtecan in patients with HER2-positive advanced breast cancer showed promising efficacy for those with brain metastases.

Gene G. Finley, MD, discusses the challenges that community oncologists are facing with small cell lung cancer treatment.

The dose and titration of ropeginterferon alfa-2b is safe and effective for patients with polycythemia vera. However, additional studies are needed to provide rationale for an amended, higher initial dosage, and rapid titration.

While project GENIE provides public access to the representation of cancer distribution among racial and ethnic minorities, findings suggest its data does not reflect the true landscape of patients with cancer and may misrepresent the disease burden across patient populations.

Melhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.

In an interview with Targeted Oncology, Andrew Kuykendall, MD, discussed the most recent approvals for MPNs, practice changing abstracts presented at ASH 2022, and what he expects to see in 2023.

After the results of the phase 2 KarMMa trial showed that idecabtagene vicleucel is a new standard of care in relapsed/refractory multiple myeloma, a real-world analysis continues to show the CAR T-cell therapy could have a wider reach.